6,7-dichloro-2-ethyl-2,3-dihydro-5-hydroxy-1H-inden-1-one | 27366-42-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚满类
• 英文名称: 6,7-dichloro-2-ethyl-2,3-dihydro-5-hydroxy-1H-inden-1-one
• 英文别名: 2-Ethyl-5-hydroxy-6,7-dichlor-1-indanon；2-ethyl-5-hydroxy-6,7-dichloro-1-indanone；2-ethyl-5-hydroxy-6,7-dichloroindanone；6,7-dichloro-2-ethyl-5-hydroxy-2,3-dihydroinden-1-one
• CAS: 27366-42-3
• 化学式: C₁₁H₁₀Cl₂O₂
• 分子量: 245.105
• InChiKey: UETRKQKDRRJRCL-UHFFFAOYSA-N

物化性质

• 熔点：
  236.8 °C(Solv: ethanol (64-17-5))
• 沸点：
  405.3±45.0 °C(Predicted)
• 密度：
  1.401±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  6,7-dichloro-2-ethyl-2,3-dihydro-5-hydroxy-1H-inden-1-one 在 盐酸 、 amalgamated zinc 作用下， 以 水 、 甲苯 为溶剂， 反应 20.0h， 以74%的产率得到6,7-dichloro-2-ethyl-2,3-dihydro-1H-inden-5-ol
  参考文献：
  名称：

  2-(Aminomethyl)phenols, a new class of saluretic agents. 5. Fused-ring analogs

  摘要：

  A number of bicyclic ring-fused analogues of 2-(aminomethyl)phenol were synthesized and tested orally in rats and intravenously in dogs for saluretic and diuretic effects. Of the 15 alicylic, aromatic, and heterocyclic ring-fused compounds tested, only 2-(aminomethyl)-4-chloro-1-naphthalenol hydrochloride (2) and 7-(aminomethyl)-6-hydroxy-5,8-dimethyl-1,2,3,4-tetrahydronaphthalene hydrochloride (6) displayed a high order of activity.

  DOI：

  10.1021/jm00358a023
• 作为产物：
  描述：

  [(6,7-二氯-2-乙基-2,3-二氢-1-氧代-1H-茚-5-基)氧基]乙酸 以80%的产率得到
  参考文献：
  名称：

  DEANA, A. A.;STOKKER, G. E.;SCHULTZ, E. M.;SMITH, R. L.;CRAGOE, E. J. ,, +, J. MED. CHEM., 1983, 26, N 4, 580-585

  摘要：

  DOI：

文献信息

• Pharmaceutical compositions and method of treatment employing
  申请人：Merck & Co., Inc.

  公开号：US03966966A1

  公开（公告）日：1976-06-29

  [1,3-Dioxo-2-substituted and 2,2-disubstituted-indanyloxy(or thio)]alkanoic acids and their salts, esters and amides are disclosed. The products display a dual pharmaceutical utility in that they exhibit diuretic, saluretic and uricosuric activity. The acid products are prepared by treating a (2- or 2,2-di)substituted-6-hydroxy-(or mercapto)-1,3-indanedione with a haloalkanoic acid or ester thereof and if the ester is employed hydrolyzing the ester.

  披露了1,3-二氧化-2-取代和2,2-二取代-茚氧（或硫）烷酸及其盐、酯和酰胺。这些产品在药用上具有双重作用，因为它们表现出利尿、排盐和利尿酸排泄活性。这些酸类产品是通过将（2-或2,2-二）取代-6-羟基（或巯基）-1,3-茚二酮与卤代烷酸或其酯反应制备的，如果使用酯，则水解酯。
• [1-Hydroxy-5-indanyloxy (or thio)]-alkanoic acids
  申请人：Merck & Co., Inc.

  公开号：US04012524A1

  公开（公告）日：1977-03-15

  [1-Hydroxy-5-indanyloxy (or thio)]alkanoic acids and their salts, esters and amides are disclosed. The products display a dual pharmaceutical utility in that they exhibit diuretic, saluretic and hypouricemic activity. The acid products are prepared by several synthetic methods.

  揭示了1-羟基-5-茚氧（或硫）烷酸及其盐、酯和酰胺。这些产品在药用上具有双重作用，表现出利尿、排钠和降尿酸活性。这些酸产品可以通过几种合成方法制备。
• (1-Oxo-7,8-disubstituted-1,2,3,4-tetrahydro-6-naphthyloxy)- and
  申请人：Merck & Co., Inc.

  公开号：US04003927A1

  公开（公告）日：1977-01-18

  (1-Oxo-7,8-disubstituted-1,2,3,4-tetrahydro-6-naphthyloxy)- and (3,4-disubstituted-5-oxo-6,7,8,9-tetrahydro-5H-benzocyclohepten-2-yloxy)ac etic acids, their carboxylate salts, and the amide and 5-tetrazole derivatives thereof are active as diuretic and saluretic agents, which also have uricosuric activity.

  "(1-Oxo-7,8-二取代-1,2,3,4-四氢-6-萘氧基)-和(3,4-二取代-5-氧代-6,7,8,9-四氢-5H-苯并环庚烯-2-氧基)乙酸，它们的羧酸盐以及其酰胺和5-四唑衍生物作为利尿和盐利尿剂具有活性，同时还具有尿酸排泄活性。"
• [1-Oxo-2-halo(or hydrogen) indanyloxy]-alkanoic acid
  申请人：Merck & Co., Inc.

  公开号：US04070539A1

  公开（公告）日：1978-01-24

  [1-Oxo-2-halo(or hydrogen)indanyloxy(or thio)]-alkanoic acid products and salts, esters and amide derivatives where the indanyl ring may be further substituted with from 2 to 5 nuclear substituents. The [1-oxo-2-haloindanyloxy-(or thio)]alkanoic acids are prepared (1) via the halogenation of a [1-oxoindanyloxy(or thio)]alkanoic acid or (2) via the addition of halogen to a [1-oxoindenyloxy(or thio)]-alkanoic acid. The [1-oxoindanyloxy(or thio)]alkanoic acids are prepared (1) via cyclialkylation of a (2-alkylideneacyl)-phenoxy(or thio)alkanoic acid or (2) via etherification of a hydroxy(or mercapto)-2-alkyl-1-indanone. The [1-oxo-2-halo(or hydrogen)indanyloxy(or thio)]alkanoic acids are diuretics and saluretics. In addition, some of these compounds are also able to maintain the uric acid concentration in the body at pretreatment level or to cause a decrease in uric acid concentration.

  [1-氧代-2-卤代(或氢)吲哚氧(或硫)基]-脂肪酸产物及其盐、酯和酰胺衍生物，其中吲哚环上可能进一步取代2-5个核取代基团。[1-氧代-2-卤代吲哚氧(或硫)基]-脂肪酸可通过以下方法制备：(1)将[1-氧代吲哚氧(或硫)基]-脂肪酸卤化或(2)将卤素添加到[1-氧代茚氧(或硫)基]-脂肪酸中。[1-氧代吲哚氧(或硫)基]-脂肪酸可通过以下方法制备：(1)将(2-烷基亚酰基)-苯氧(或硫)基脂肪酸環化或(2)将羟基(或巯基)-2-烷基-1-茚酮醚化。[1-氧代-2-卤代(或氢)吲哚氧(或硫)基]-脂肪酸具有利尿和盐利尿作用。此外，其中一些化合物还能够维持体内尿酸浓度在治疗前的水平或引起尿酸浓度下降。
• US3966966A
  申请人：——

  公开号：US3966966A

  公开（公告）日：1976-06-29